Shareholder voteRegulatory filing
What was reported
On June 9, 2026, the Company held its Annual Meeting. At the Annual Meeting, the Company’s stockholders voted on three proposals, all of which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”).U.S. Securities and Exchange Commission (EDGAR) · 8-K: FORM 8-K · Jun 9, 2026 · Open the source ↗
What the evidence supports
Humacyte told the SEC (Form 8-K, Item 5.07) that its shareholders voted on matters put to them, and what the outcome was. The filing gives Jun 9, 2026 as the date of the earliest event reported.
What remains unknown
How individual shareholders voted, and what the company will do next beyond what it disclosed.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.07 textOn June 9, 2026, the Company held its Annual Meeting. At the Annual Meeting, the Company’s stockholders voted on three proposals, all of which are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”).U.S. Securities and Exchange Commission (EDGAR) · 8-K: FORM 8-K · Jun 9, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:52 UTC
Humacyte reports results of a shareholder vote (Form 8-K, Item 5.07)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.